MicroRNAs como biomarcadores de diagnóstico, pronóstico y predicción en cáncer de mama
Palabras clave:
Cáncer de mama, biomarcadores, miRNAsResumen
El cáncer de mama es el tipo de cáncer más común en mujeres y tiene un gran impacto en la salud pública a nivel mundial. Debido a su naturaleza compleja y altamente heterogénea, es primordial realizar un diagnóstico rápido y efectivo para determinar el pronóstico de la enfermedad y administrar el tratamiento adecuado a los pacientes. El uso de microRNAs como biomarcadores podría facilitar el diagnóstico y pronóstico de esta enfermedad. Debido a sus múltiples características, los microRNAs son candidatos ideales para ser implementados como biomarcadores en cáncer. En este artículo revisamos la importancia de los microRNAs como biomarcadores de diagnóstico, pronóstico y predicción en el cáncer de mama.
Descargas
Citas
Ahmad, A. (Ed.). (2019). Breast Cancer Metastasis and Drug Resistance: Challenges and Progress (Vol. 1152). Springer International Publishing. https://doi.org/10.1007/978-3-030-20301-6
American Cancer Society. (s. f.). Breast Cancer Facts & Figures 2019-2020.
Andorfer, C. A., Necela, B. M., Thompson, E. A., & Perez, E. A. (2011). MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends in Molecular Medicine, 17(6), 313-319. https://doi.org/10.1016/j.molmed.2011.01.006
Bartel, D. P. (2004). MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell, 116(2), 281-297. https://doi.org/10.1016/S0092-8674(04)00045-5
Bertoli, G., Cava, C., & Castiglioni, I. (2015). MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics, 5(10), 1122-1143. https://doi.org/10.7150/thno.11543
Chakrabortty, A., Patton, D. J., Smith, B. F., & Agarwal, P. (2023). miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer. Genes, 14(7), Article 7. https://doi.org/10.3390/genes14071375
Christodoulatos, G. S., & Dalamaga, M. (2014). Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World Journal of Clinical Oncology, 5(2), 71-81. https://doi.org/10.5306/wjco.v5.i2.71
Dong, G., Liang, X., Wang, D., Gao, H., Wang, L., Wang, L., Liu, J., & Du, Z. (2014). High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Medical Oncology (Northwood, London, England), 31(7), 57. https://doi.org/10.1007/s12032-014-0057-x
Finnegan, E. F., & Pasquinelli, A. E. (2013). MicroRNA biogenesis: Regulating the regulators. Critical Reviews in Biochemistry and Molecular Biology, 48(1), 51-68. https://doi.org/10.3109/10409238.2012.738643
Gasparini, P., Cascione, L., Fassan, M., Lovat, F., Guler, G., Balci, S., Irkkan, C., Morrison, C., Croce, C. M., Shapiro, C. L., & Huebner, K. (2014). microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget, 5(5), 1174-1184. https://doi.org/10.18632/oncotarget.1682
Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022). MicroRNA-Based Diagnosis and Therapy. International Journal of Molecular Sciences, 23(13), Article 13. https://doi.org/10.3390/ijms23137167
Hu, J., Xu, J., Wu, Y., Chen, Q., Zheng, W., Lu, X., Zhou, C., & Jiao, D. (2015). Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 36(1), 251-258. https://doi.org/10.1007/s13277-014-2611-8
Hu, Z., Dong, J., Wang, L.-E., Ma, H., Liu, J., Zhao, Y., Tang, J., Chen, X., Dai, J., Wei, Q., Zhang, C., & Shen, H. (2012). Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis, 33(4), 828-834. https://doi.org/10.1093/carcin/bgs030
INEGI. (s. f.). Instituto Nacional de Estadística y Geografía. INEGI. Recuperado 29 de noviembre de 2023, de https://www.inegi.org.mx/app/saladeprensa/noticia.html?id=8498
Institut Claudius Regaud. (2018). Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer? Pilot Study. (Clinical trial registration NCT01612871). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT01612871
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., Ménard, S., Palazzo, J. P., Rosenberg, A., Musiani, P., Volinia, S., Nenci, I., Calin, G. A., Querzoli, P., Negrini, M., & Croce, C. M. (2005). MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 65(16), 7065-7070. https://doi.org/10.1158/0008-5472.CAN-05-1783
Jung, E.-J., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., Di Leo, A., Le, X.-F., Bast, R. C., Park, S.-T., Pusztai, L., & Calin, G. A. (2012). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118(10), 2603-2614. https://doi.org/10.1002/cncr.26565
Krishnan, P., Ghosh, S., Wang, B., Li, D., Narasimhan, A., Berendt, R., Graham, K., Mackey, J. R., Kovalchuk, O., & Damaraju, S. (2015). Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics, 16(1), 735. https://doi.org/10.1186/s12864-015-1899-0
Kulasingam, V., & Diamandis, E. P. (2008). Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature Clinical Practice. Oncology, 5(10), 588-599. https://doi.org/10.1038/ncponc1187
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), Article 5. https://doi.org/10.1016/0092-8674(93)90529-Y
Lujambio, A., & Lowe, S. W. (2012). The microcosmos of cancer. Nature, 482(7385), Article 7385. https://doi.org/10.1038/nature10888
Lyng, M. B., Lænkholm, A.-V., Søkilde, R., Gravgaard, K. H., Litman, T., & Ditzel, H. J. (2012). Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: A DBCG study. PloS One, 7(5), e36170. https://doi.org/10.1371/journal.pone.0036170
Moazed, D. (2009, enero 21). Small RNAs in transcriptional gene silencing and genome defence [Special Features]. Nature. https://doi.org/10.1038/nature07756
NCI (nciglobal,ncienterprise). (2011, febrero 2). [nciAppModulePage]. https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/biomarcador
Peng, S., Wang, J., Wei, S., Li, C., Zhou, K., Hu, J., Ye, X., Yan, J., Liu, W., Gao, G. F., Fang, M., & Meng, S. (2018). Endogenous Cellular MicroRNAs Mediate Antiviral Defense against Influenza A Virus. Molecular Therapy - Nucleic Acids, 10, 361-375. https://doi.org/10.1016/j.omtn.2017.12.016
Provenzano, E., Ulaner, G. A., & Chin, S.-F. (2018). Molecular Classification of Breast Cancer. PET Clinics, 13(3), Article 3. https://doi.org/10.1016/j.cpet.2018.02.004
Purkayastha, K., Dhar, R., Pethusamy, K., Srivastava, T., Shankar, A., Rath, G. K., & Karmakar, S. (2023). The issues and challenges with cancer biomarkers. Journal of Cancer Research and Therapeutics, 19(Suppl 1), S20. https://doi.org/10.4103/jcrt.jcrt_384_22
Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K., & Schwarzenbach, H. (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research: BCR, 12(6), R90. https://doi.org/10.1186/bcr2766
Rothé, F., Ignatiadis, M., Chaboteaux, C., Haibe-Kains, B., Kheddoumi, N., Majjaj, S., Badran, B., Fayyad-Kazan, H., Desmedt, C., Harris, A. L., Piccart, M., & Sotiriou, C. (2011). Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PloS One, 6(6), e20980. https://doi.org/10.1371/journal.pone.0020980
Sarhadi, V. K., & Armengol, G. (2022). Molecular Biomarkers in Cancer. Biomolecules, 12(8), Article 8. https://doi.org/10.3390/biom12081021
Sell, S. (2003). Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Eleftherios P. Diamandis, Hervert A. Fritche, Hans Lilja, Daniel W. Chan, and Morton K. Schwartz, eds. Washington, DC: AACC Press, 2002, 513 pp., $99.00 ($79.00 AACC members), softcover. ISBN 1-890883-71-9. Clinical Chemistry, 49(2), 342. https://doi.org/10.1373/49.2.342
Siervi, A. D. (2022). Onco-liq: Kit for Breast Cancer Diagnosis. (Clinical trial registration NCT04906330). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT04906330
Strimbu, K., & Tavel, J. A. (2010). What are Biomarkers? Current opinion in HIV and AIDS, 5(6), 463-466. https://doi.org/10.1097/COH.0b013e32833ed177
Sun, Y., Wang, M., Lin, G., Sun, S., Li, X., Qi, J., & Li, J. (2012). Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PloS One, 7(10), e47003. https://doi.org/10.1371/journal.pone.0047003
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, n/a(n/a), Article n/a. https://doi.org/10.3322/caac.21660
Tang, J., Ahmad, A., & Sarkar, F. H. (2012). The role of microRNAs in breast cancer migration, invasion and metastasis. International Journal of Molecular Sciences, 13(10), 13414-13437. https://doi.org/10.3390/ijms131013414
Tsang, J. Y. S., & Tse, G. M. (2020). Molecular Classification of Breast Cancer. Advances in Anatomic Pathology, 27(1), Article 1. https://doi.org/10.1097/PAP.0000000000000232
Valabrega, G., Montemurro, F., & Aglietta, M. (2007). Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 18(6), 977-984. https://doi.org/10.1093/annonc/mdl475
Wu, Q., Lu, Z., Li, H., Lu, J., Guo, L., & Ge, Q. (2011). Next-generation sequencing of microRNAs for breast cancer detection. Journal of Biomedicine & Biotechnology, 2011, 597145. https://doi.org/10.1155/2011/597145
Zhao, F., Dou, Y., Wang, X., Han, D., Lv, Z., Ge, S., & Zhang, Y. (2014). Serum microRNA-195 is down-regulated in breast cancer: A potential marker for the diagnosis of breast cancer. Molecular Biology Reports, 41(9), 5913-5922. https://doi.org/10.1007/s11033-014-3466-1
